Can "statins" be used in patients with hepatitis B?

Postgraduate Medicine

Volumn 111, Issue 5, 2002, Pages 119-120

  Safeer, Richard S ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; HEPATITIS B; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; MYOPATHY; NOTE; RHABDOMYOLYSIS;

EID: 0036096053     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2002.05.1217     Document Type: Note

References (9)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary artery disease and a broad range of initial cholesterol levels
2. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
5. Effects of hepatic and renal impairment on pharmacokinetics and pharmacodynamics of atorvastatin